NCT05389696View on ClinicalTrials.gov

Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 13, 2022

Primary Completion Date

February 13, 2023

Study Completion Date

April 28, 2023

Conditions
Heathly Subjects
Interventions
DRUG

Single subcutaneous administration and Blood collection

Single subcutaneous administration and Blood collection

DRUG

Single subcutaneous administration and then IV injection.

Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.

DRUG

MIT-001 20mg and 40mg_Multiple administration

Multiple subcutaneous administration for 7 days and then blood collection

Trial Locations (1)

03080

Seoul National University, Seoul

Sponsors
All Listed Sponsors
lead

MitoImmune Therapeutics

INDUSTRY

NCT05389696 - Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects | Biotech Hunter | Biotech Hunter